Evidence map›Paper›PMID 40797208›Full record

ArticleJournal of nanobiotechnology2025

Radiocleavable rare-earth nanoactivators targeting over-expressed folate receptors induce mitochondrial dysfunction and remodel immune suppressive microenvironment in pancreatic cancer.

Tanvi Gupta, Shang-Rung Wu, Li-Chan Chang, Forn-Chia Lin, Yan-Shen Shan, Chen-Sheng Yeh, Wen-Pin Su

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tanvi GuptaInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, No. 35, Rd. Xiaodong, Tainan, 704, Taiwan.
Shang-Rung WuSchool of Dentistry & Institute of Oral Medicine, College of Medicine, National Cheng Kung University, Tainan City, 701, Taiwan.
Li-Chan ChangInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, No. 35, Rd. Xiaodong, Tainan, 704, Taiwan.
Forn-Chia LinDepartment of Radiation Oncology, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, 704, Taiwan.
Yan-Shen ShanInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, No. 35, Rd. Xiaodong, Tainan, 704, Taiwan.
Chen-Sheng YehDepartment of Chemistry, National Cheng Kung University, Tainan, 701, Taiwan.
Wen-Pin SuInstitute of Clinical Medicine, College of Medicine, National Cheng Kung University, No. 35, Rd. Xiaodong, Tainan, 704, Taiwan. wpsu@mail.ncku.edu.tw.

Funding

National Cheng Kung University Hospital 11410012National Science and Technology Council 113-2314-B-006-038-MY3National Science and Technology Council 114-2124-M-006-007
6 · The paper itself

Abstract

Pancreatic cancer is a fatal cancer with poor prognosis and survival rate, often diagnosed usually in the advanced stage of disease. The conventional methods are usually considered for surgery or chemotherapy, and neo-adjuvant therapies have improved the survival rate in the patients. Folic acid plays a crucial role in the synthesis, metabolism, and repair of DNA; thereby, it is considered one of the biomolecules for cancer-targeted therapy for highly expressed receptors to overcome poor vasculature and dense tumor stroma, as in pancreatic cancer. This study strategizes for improving the therapeutic efficacy of pancreatic cancer via folate receptor-guided nanoparticles. The conjugation of folic acid (FA) to the LiYF

Indexed as

Folate Receptors, GPI-AnchoredMetals, Rare EarthMitochondriaNanoparticlesPancreatic NeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorFolic AcidHumansMembrane Potential, MitochondrialMiceReactive Oxygen SpeciesFolate Receptors, GPI-AnchoredFolic AcidMetals, Rare EarthReactive Oxygen SpeciesFerroptosisFolate receptorFolic acidImmunogenic cell deathNano therapy

Identifiers

PMID40797208
PMCPMC12341285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.